- Markets
- Trading
- BRAWN
BRAWN
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Brawn Biotech do?
Brawn Biotech Ltd is a pharmaceutical company engaged in manufacturing tablets, capsules, and oral syrups across various categories including Analgesics, Antibiotics, and Cardiovascular drugs.
Who are the competitors of Brawn Biotech?
Brawn Biotech major competitors are Padmanabh Industries, Unitech Internationa, PAE, Ashiana Agro, Atharv Enterprises, Voltaire Leasing, Centron Indl. Allian. Market Cap of Brawn Biotech is ₹5 Crs. While the median market cap of its peers are ₹5 Crs.
Is Brawn Biotech financially stable compared to its competitors?
Brawn Biotech seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Brawn Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Brawn Biotech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Brawn Biotech allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Brawn Biotech balance sheet?
Balance sheet of Brawn Biotech is moderately strong.
Is the profitablity of Brawn Biotech improving?
No, profit is decreasing. The profit of Brawn Biotech is -₹1.65 Crs for TTM, -₹1.24 Crs for Mar 2024 and -₹0.91 Crs for Mar 2023.
Is the debt of Brawn Biotech increasing or decreasing?
Yes, The debt of Brawn Biotech is increasing. Latest debt of Brawn Biotech is -₹0.24 Crs as of Sep-24. This is greater than Mar-24 when it was -₹0.79 Crs.
Is Brawn Biotech stock expensive?
Brawn Biotech is not expensive. Latest PE of Brawn Biotech is 0.0, while 3 year average PE is 1.66. Also latest EV/EBITDA of Brawn Biotech is 0.0 while 3yr average is 5.33.
Has the share price of Brawn Biotech grown faster than its competition?
Brawn Biotech has given better returns compared to its competitors. Brawn Biotech has grown at ~0.69% over the last 10yrs while peers have grown at a median rate of -10.17%
Is the promoter bullish about Brawn Biotech?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 53.66% and last quarter promoter holding is 53.64%.
Are mutual funds buying/selling Brawn Biotech?
The mutual fund holding of Brawn Biotech is stable. The current mutual fund holding in Brawn Biotech is 0.35% while previous quarter holding is 0.35%.